Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting Nasdaq:OCUP

Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting Nasdaq:OCUP

News Highlights

Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization

New Data from Physiological-Based Pharmacokinetic (PBPK) Model Supports APX3330 Oral Dose for the Ongoing ZETA-1 Phase 2 Trial

FARMINGTON HILLS, Mich., April 22, 2021 (News) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that data from pre-clinical studies and pharmacokinetic modeling of the Company’s proprietary APX3330 drug candidate will be presented on Sunday, May 2, 2021 during the upcoming Association for Research in Vision and Ophthalmology (ARVO) virtual Annual Meeting, May 1 – 7, 2021.

Details of the abstract and presentation are as follows:

Title: Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modelingSession: Diabetic RetinopathyPresentation Type: Paper PresentationDate: 11:15 AM – 12:45 PM EDT on Sunday, May 2

On Saturday, May 1, 2021 at 7:00 AM ET, the virtual presentations will be available on demand to registered attendees of the ARVO Annual Meeting. Ocuphire plans to post the APX3330 abstract presentation to Ocuphire’s website under Posters and Publications.

Data from this pre-clinical study showed that oral administration of APX3330 was effective in reducing laser-induced choroidal neovascularization (L-CNV) in a mouse model, which is a widely validated model for studying antiangiogenic therapies. Additionally, new data will be presented from PBPK modeling that confirmed the dosing strategy for the ongoing ZETA-1 Phase 2 trial in patients with diabetic retinopathy (DR) and diabetic macular edema (DME).

Dr. Mark R. Kelley, Professor in the Department of Pediatrics and Glick Eye Institute at Indiana University School of Medicine, founder of the APX3330 program, and member of Ocuphire’s Medical Advisory Board stated, “We are very pleased to share new data on the PBPK modeling results of APX3330 which quantitatively predict the amount of drug that would be reaching the retina. At present, DR patients are less frequently treated with anti-VEGF intravitreal injections, so we are excited to initially develop APX3330 as a potential oral treatment option for DR patients.”

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 8 clinical trials including the recently completed Phase 3 trial in RM. Ocuphire reported positive topline data on March 15, 2021 for MIRA-2 Phase 3 FDA registration study for treatment of RM. Nyxol is also currently in Phase 3 clinical development for NVD and in Phase 2 for presbyopia. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 has entered Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 trials, recently completed Phase 3 registration trial (NCT04620213), ongoing Phase 3 registration trial (NCT04638660), Phase 2 trial in presbyopia (NCT04675151), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates, results of ongoing and future clinical trials, and commercialization and market opportunities. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, and (ix) the success and timing of commercialization of any of Ocuphire’s product candidates. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Ocuphire Contacts

Mina Sooch, President & CEO Ocuphire Pharma, Inc. ir@ocuphire.com www.ocuphire.com  

Corey Davis, Ph.D.LifeSci Advisorscdavis@lifescieadvisors.com

  • Check the latest Health news updates and information.
  • Please share this news Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting Nasdaq:OCUP with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
To improve Dogecoin security Elon Musk comes forward

To improve Dogecoin security Elon Musk comes forward

Dogecoin was made as a meme and is not particularly known for its security. The creator of the coin said that he made the currency in just 2 hours, and he ...
Sports calendar for May 14 in downtown New York

Sports calendar for May 14 in downtown New York

Oppenheim-Ephratah-St. Johnsville at Berne-Knox-Westerlo, 4:30 p.m. Frankfort-Schuyler at Cooperstown, 4:30 p.m. Richfield Springs at Milford, 4:30 p.m. ...
Large companies that need employees offer to pay more

Large companies that need employees offer to pay more

“For Georgia to continue to be the No. 1 state in the business, we got to be more productive than we are not right now,” Georgia Gov. Brian Kemp said. “We ...
On Mideast, After US Delay UN Security Council  are up for Meeting on Sunday 

On Mideast, After US Delay UN Security Council  are up for Meeting on Sunday 

The United States said earlier Thursday it wanted to give time for diplomacy. (File)   The UN Security Council will hold a virtual public meeting Sunday to ...
Tellurian, Syneos Health See Activist Action

Tellurian, Syneos Health See Activist Action

(TOT) reduced its stake in Tellurian, a natural-gas producer, also involved with liquefied-natural-gas trading and infrastructure. Total sold 4,555,512 ...
Maximizing business deductions on tax day

Maximizing business deductions on tax day

■However, if your business is an S corporation and if, as is often the case, you yourself are one of its employees, you will have to determine the maximum ...
The NIH Director Advisory Committee advances the AI ​​and Health Equity program

The NIH Director Advisory Committee advances the AI ​​and Health Equity program

The ACD members unanimously approved the concept, clearing the way for NIH staff to develop a research funding opportunity to be announced this summer, ...
Missouri passes COVID-19 liability shield to companies

Missouri passes COVID-19 liability shield to companies

The bill was a priority for business groups. “This actually should have been the first bill we passed at the beginning of the year,” said House Speaker Pro ...
Kingdom Hearts games on PC need to be fixed as soon as possible

Kingdom Hearts games on PC need to be fixed as soon as possible

I am thankful to play this PC port with my Dualshock 4, but being restricted to only this controller without the option to switch over to other controllers I ...
Ireland refuses to pay ransom in attack on its national health service

Ireland refuses to pay ransom in attack on its national health service

The attack had a severe impact on the country’s health and social care services on Friday, but emergency services continued to operate normally, according to ...
Show next
Compsmag - Latest News from tech, business and health
Logo